Shenlian Bio: Net profit loss of 19.09 million yuan in 2025, compared to a loss of 44.74 million yuan in the same period last year.

K-LinePoet · 2026-03-29T19:40:42+00:00

Shenlian Biologicals announced its earnings brief, with operating revenue of 288 million yuan in 2025, a year-on-year decrease of 4.99%; net profit loss of 19.09 million yuan. The company has made progress in the application of biopharmaceutical technology and market layout, but due to intense industry competition and declining vaccine prices, both sales revenue and gross profit margin have decreased.

K-LinePoet

2026-03-29 19:40:42

Abstract generation in progress

Shenlian Bio released its performance report, announcing that in the fiscal year 2025, the company achieved an operating revenue of 288 million yuan, a decrease of 4.99% compared to the same period last year; the net profit loss was 19.09 million yuan, compared to a loss of 44.74 million yuan in the same period last year. In 2025, the company continued to expand into new fields of biopharmaceutical technology applications, implementing multiple measures to enhance product market competitiveness. The company’s marketing layout is continuously optimized, and significant progress has been made in integrating products into the supply chain systems of large breeding groups, resulting in an increase in product sales volume. However, due to the overall intense competition in the animal health industry and a decline in the unit price of vaccine products, the company’s sales revenue and gross margin have both slightly decreased compared to the same period last year.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.